OBJECTIVES: The purpose of this study was to demonstrate the feasibility and procedural outcomes with a new self-expanding and repositionable transcatheter heart valve. BACKGROUND: Transcatheter aortic valve replacement is a viable option for selected patients with severe symptomatic aortic stenosis. However, suboptimal prosthesis positioning may contribute to paravalvular regurgitation, atrioventricular conduction block, and mitral or coronary compromise. METHODS: The repositionable Portico valve (St. Jude Medical, Minneapolis, Minnesota) was implanted in 10 patients with severe aortic stenosis utilizing percutaneous femoral arterial access. Patients underwent transthoracic and transesophageal echocardiography and multidetector computed tomography before and after valve implantation. Clinical and echocardiographic follow-up was obtained at 30 days. RESULTS: Device implantation was successful in all patients. Prosthesis recapture and repositioning was performed in 4 patients. Intermittent prosthetic leaflet dysfunction in 1 patient required implantation of a second transcatheter valve. There was 1 minor stroke. At 30-day follow-up, echocardiographic mean transaortic gradient was reduced from 44.9 ± 16.7 mm Hg to 10.9 ± 3.8 mm Hg (p < 0.001), and valve area increased from 0.6 ± 0.1 cm(2) to 1.3 ± 0.2 cm(2) (p < 0.001). Paravalvular regurgitation was mild or less in 9 patients (90%) and moderate in 1 patient (10%). There were no major strokes, major vascular complications, major bleeds, or deaths. No patient required pacemaker implantation. All patients were in New York Heart Association functional class II or less. CONCLUSIONS: Transcatheter aortic valve replacement with the repositionable Portico transcatheter heart valve is feasible, with good short-term clinical and hemodynamic outcomes.
OBJECTIVES: The purpose of this study was to demonstrate the feasibility and procedural outcomes with a new self-expanding and repositionable transcatheter heart valve. BACKGROUND: Transcatheter aortic valve replacement is a viable option for selected patients with severe symptomatic aortic stenosis. However, suboptimal prosthesis positioning may contribute to paravalvular regurgitation, atrioventricular conduction block, and mitral or coronary compromise. METHODS: The repositionable Portico valve (St. Jude Medical, Minneapolis, Minnesota) was implanted in 10 patients with severe aortic stenosis utilizing percutaneous femoral arterial access. Patients underwent transthoracic and transesophageal echocardiography and multidetector computed tomography before and after valve implantation. Clinical and echocardiographic follow-up was obtained at 30 days. RESULTS: Device implantation was successful in all patients. Prosthesis recapture and repositioning was performed in 4 patients. Intermittent prosthetic leaflet dysfunction in 1 patient required implantation of a second transcatheter valve. There was 1 minor stroke. At 30-day follow-up, echocardiographic mean transaortic gradient was reduced from 44.9 ± 16.7 mm Hg to 10.9 ± 3.8 mm Hg (p < 0.001), and valve area increased from 0.6 ± 0.1 cm(2) to 1.3 ± 0.2 cm(2) (p < 0.001). Paravalvular regurgitation was mild or less in 9 patients (90%) and moderate in 1 patient (10%). There were no major strokes, major vascular complications, major bleeds, or deaths. No patient required pacemaker implantation. All patients were in New York Heart Association functional class II or less. CONCLUSIONS: Transcatheter aortic valve replacement with the repositionable Portico transcatheter heart valve is feasible, with good short-term clinical and hemodynamic outcomes.
Authors: Maurizio Taramasso; Alberto Pozzoli; Azeem Latib; Giovanni La Canna; Antonio Colombo; Francesco Maisano; Ottavio Alfieri Journal: Nat Rev Cardiol Date: 2014-01-21 Impact factor: 32.419
Authors: Hoda Hatoum; Shelley Gooden; Megan Heitkemper; Kevin M Blum; Jason Zakko; Martin Bocks; Tai Yi; Yen-Lin Wu; Yadong Wang; Christopher K Breuer; Lakshmi Prasad Dasi Journal: Ann Biomed Eng Date: 2020-02-12 Impact factor: 3.934
Authors: Brian R Englum; Asvin M Ganapathi; Matthew A Schechter; J Kevin Harrison; Donald D Glower; G Chad Hughes Journal: Ann Thorac Surg Date: 2015-09-16 Impact factor: 4.330
Authors: Robert M A van der Boon; Patrick Houthuizen; Rutger-Jan Nuis; Nicolas M van Mieghem; Frits Prinzen; Peter P T de Jaegere Journal: Curr Cardiol Rep Date: 2014-01 Impact factor: 2.931
Authors: Paul S Gunning; Neelakantan Saikrishnan; Ajit P Yoganathan; Laoise M McNamara Journal: J R Soc Interface Date: 2015-12-06 Impact factor: 4.118